Aniling, IGTP and ICO awarded €1.8 million from the Spanish government to develop a theragnostic tool for personalised management of colorectal cancer
The consortium made up of Aniling, the Germans Trias i Pujol Research Institute (IGTP) and the Institut Català d'Oncologia (ICO) has been awarded €1.8 million from the Spanish State Research Agency (AEI)1 for the development of a new theragnostic tool to personalise the management of colorectal cancer (CRC) patients. The funds are from a competitive call through the 2021 State Programme to Promote Scientific- Technical Research and its Transfer (formerly known as Retos Colaboración).
Aniling will coordinate the project that will be carried out between 2023 and 2025. This clinical-stage biotech company, founded in 2014, is specialised in discovery and development of solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology.
The project aims to develop an innovative platform that can generate and use organoid models to enable personalised testing of various drugs, allowing clinicians to predict how each patient will respond to different treatments.
Additionally, the project will produce a companion diagnostic test that precisely profiles colorectal cancer at a molecular level, with a focus on genomic and epigenomic biomarkers. This innovative approach will generate a new set of biomarkers and algorithms which have the potential to improve treatment selection and, ultimately, cancer care.
With these advancements, Aniling will be able to develop a comprehensive commercial kit that includes reagents, protocols, and computational analysis tools. This kit will help streamline and optimize the process of generating and analysing organoids, as well as profiling CRC at a molecular level. Ultimately, this kit will contribute to the personalised management of CRC and potentially other types of cancer in the future.
The new tool will be incorporated into Aniling's pipeline, which currently consists of three in vitro diagnostic (IVD) tests for chronic lymphocytic leukaemia (GEUS-CLL), colorectal cancer (GEUS-CRC) and liquid biopsy (GEUS-LB) with CE-certification from the European Union.
1 MCIN/AEI /10.13039/501100011033 Next Generation EU/PRTR (CPP2021-008602).
Aniling is a spin-off committed to bringing advances in the Genomics arena to everyday health care and disease prevention. The aim of Aniling is to accelerate epigenomics to help make precision medicine a reality. Aniling has patented the GEUS technology (Genomic and Epigenomic Unified Sequencing), which allows for the ﬁrst time simultaneous and high-reliability analysis of genome and epigenome, and provides end-to-end solutions for the right treatment decisions in oncology.